Approximately one-third of human breast cancers in the advanced stage respond objectively to endocrine therapy, which usually involves oestrogen deprivation or inhibition.
In post-menopausal women, the prime source of oestrogens is through the peripheral conversion of androgens by the aromatase enzyme, mainly in fat and muscle tissues (Longcope et al., 1978; Longcope, 1982) . Inhibition of aromatase is now accepted as an effective treatment in post-menopausal breast cancer patients (Dowsett, 1990) . Furthermore, it has been reported that approximately twothirds of human breast cancers contain measurable, although relatively low, aromatase activity (Lipton et al., 1987) .
Aminoglutethimide (AG) has been used for a number of years in the treatment of advanced post-menopausal breast cancer (Santen et al., 1974) . It is an efficient inhibitor of aromatase, achieving more than 90% inhibition of the enzyme, as assessed by isotopic infusion techniques (Santen et al., 1978; Macneill et al., 1992) . However, this drug inhibits cholesterol side-chain cleavage in the adrenal glands (e.g. , as well as inhibition of aromatase (Goss and Gwyn, 1994) . The resulting suppression of steroidogenesis has led to its combined use with replacement doses of glucocorticoid (Murray and Pitt, 1985) . Moreover, substantial side-effects associated with the use of AG (even with low doses) have been reported (Stuart-Harris and Smith, 1984a) . This has resulted in the development of a number of other aromatase inhibitors, with high selectivity and fewer toxic side-effects.
These new inhibitors may be divided into two groups: steroidal and non-steroidal compounds. Fadrozole hydrochloride, CGS 16949A, a tetrahydroimidazole-pyridine derivative is a non-steroidal inhibitor of aromatase. In preclinical studies it was found to be 400 times more potent than AG (Steele et al., 1987) . Phase I studies reported an excellent tolerability (Lipton et al., 1990; Beretta et al., 1990; Santen et al., 1989) . Daily fadrozole doses of 2 mg were associated with a maximum oestrogen suppression (Lipton et al., 1990; Beretta et al., 1990) . In one study, Santen et al. (1989) have shown that aldosterone suppression occurred only at substantially higher doses than those required for maximum oestrogen suppression (8 and 16 mg day-'). Two phase II studies did not show a significant difference in toxicity or response between 1 mg day-' and 4 mg day-1 in one study or between 1, 2 and 4 mg day-' in the other study (Raats et al., 1992; Hoeffken et al., 1992) . In contrast, our preliminary clinical investigations with this compound indicated that there was a dose-related suppression of oestradiol levels between the doses of 0.6 and 4 mg day-1 and that aldosterone levels were suppressed by approximately 50% at the 4 mg day-1 dose Stein et al., 1990) . In order to clarify this point we decided to conduct a study with CGS used as second-line therapy in postmenopausal patients with metastatic breast cancer. Treatment allocation was randomly 1, 2 or 4 mg day-1 orally of fadrozole. The primary objective was to quantify the dose relationship of CGS with respect to plasma oestrogen suppression and a broad spectrum of endocrine analysis. These results have been recently published (Dowsett et al., 1994 The following disease assessments were made at baseline and every 3 months thereafter: physical examination, photographs of all visible lesions, chest radiograph, liver ultrasound (or CAT scan), bone scintigram and skeletal radiographs (if indicated).
Toxicity was assessed using WHO criteria (WHO, 1979) and response was assessed using UICC criteria (Hayward et al., 1977) . Table II . Two patients were withdrawn from trial treatment owing to poor tolerance: one because of depression and the other because of lethargy. No serious adverse experiences were reported. There was no statistically significant effect on either plasma sodium or potassium levels at 1 month and 3 months. Minor changes occurred, which were reflected in the sodium -potassium ratio with a significant difference between the 1 and 3 month means. Nevertheless, these differences were not consistent across the dose groups. None of these small effects on sodium, potassium and the sodiumpotassium ratio were clinically relevant.
Similarly, there was no significant change in cortisol and aldosterone levels for all these dose groups.
Response Among clinically evaluable patients (72 patients), 12 patients (17%) had partial responses (PRs) (95% CI 8.9-27.3%), with no complete responders. Fifteen patients (21%) had stable disease (NC) and 45 patients (63%) had progressive Time to treatmentfailure (TTF) TTF was calculated in days from the first day of treatment to the date of withdrawal from the trial for any reason (e.g. disease progression, death, lack of tolerance to treatment).
The median TTF was 12.7 weeks. The log-rank test showed no statistically significant differences between the dosage groups. The recording of overall survival was not a trial objective.
Discussion
This study has shown that fadrozole is a clinically active aromatase inhibitor with a response rate of 17% (95% CI 9-27%) in previously treated patients. This confirms experience in two similar studies with response rates respectively of 23% (95% CI 12-34%) and 16% (95% CI 12-20%) (Raats et al., 1992; Hoeffken et al., 1992) . For second-line endocrine therapy these results may be slightly lower than for some other published reports on aromatase inhibitors, including aminoglutethimide (Powles, 1983; Stuart-Harris and Smith, 1984b; Miller, 1989) and 4-hydroxyandrostenedione (Goss and Gwyn, 1994) . The confidence intervals, however, in this study and in the other two (Raats et al., 1992; Hoeffken et al., 1992) are wide, ranging from 9% to 34%. In addition, a comparison of response rates from second-line hormonal therapies used in different studies does not allow conclusions about the 'best second-line hormonal agent' because of possible selection bias, including the number of nonresponders to first-line endocrine therapy (Powles, 1983) . Comparative phase III trials are required to answer this question and these are under way. Moreover, in a trial comparing fadrozole with tamoxifen as first-line treatment (Thiirlimann et al., 1995) no statistically significant difference in terms of response rate emerged between these two agents (16% and 24% respectively). However, the median time to failure was shorter with fadrozole compared with tamoxifen (4.9 months vs 8.3 months), but not statistically significant (P=0.10).
The response rates in patients receiving 0.5 mg, 1 mg and 2 mg of fadrozole twice daily were respectively 13.1%, 16.7% and 20.0%. The design of our study and patient numbers involved do not allow dose -response conclusions to be drawn. Raats et al. (1992) conducted a study in which the patients were randomised to receive fadrozole 0.5 mg b.d. or 2 mg b.d. The study was designed in order to detect a 30% difference in response rate between the two regimens with a power of 80%; no significant difference was found.
This study has also confirmed that fadrozole is a welltolerated agent with a low incidence of side-effects. The small number of side-effects reported (nausea, somnolence, hot flushes) were of low WHO grade and a causal relationship with fadrozole was often uncertain. Two patients stopped therapy because of side-effects (somnolence, depression) but again a causal relationship remained uncertain. These sideeffects did not appear to be dose related. Others have also reported the low incidence of side-effects with fadrozole (Raats et al., 1992; Hoeffken et al., 1992) and this contrasts favourably with past experience with aminoglutethimide sideeffects (Stuart-Harris and Smith, 1984b).
In conclusion, fadrozole is a clinically active aromatase inhibitor with a low incidence of side-effects.
